PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17593930-2 2008 In the mu-opioid receptor (MOR) binding study and G-protein activation, we confirmed that both morphine and oxycodone showed MOR agonistic activities. Oxycodone 108-117 opioid receptor, mu 1 Mus musculus 7-25 17593930-2 2008 In the mu-opioid receptor (MOR) binding study and G-protein activation, we confirmed that both morphine and oxycodone showed MOR agonistic activities. Oxycodone 108-117 opioid receptor, mu 1 Mus musculus 125-128 17593930-2 2008 In the mu-opioid receptor (MOR) binding study and G-protein activation, we confirmed that both morphine and oxycodone showed MOR agonistic activities. Oxycodone 108-117 opioid receptor, mu 1 Mus musculus 27-30 33031806-0 2020 Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration. Oxycodone 122-131 opioid receptor, mu 1 Mus musculus 46-51 33031806-0 2020 Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration. Oxycodone 122-131 opioid receptor, mu 1 Mus musculus 53-71 33031806-1 2020 The widely abused prescription opioid oxycodone is a mu-opioid receptor (MOP-r) agonist and addiction to such opioids is a relapsing disorder. Oxycodone 38-47 opioid receptor, mu 1 Mus musculus 53-71 33031806-1 2020 The widely abused prescription opioid oxycodone is a mu-opioid receptor (MOP-r) agonist and addiction to such opioids is a relapsing disorder. Oxycodone 38-47 opioid receptor, mu 1 Mus musculus 73-78 33031806-10 2020 We also detected differences in MOP-r gene expression due to genotype, sex and oxycodone SA history in the dorsal striatum, hippocampus, and prefrontal cortex. Oxycodone 79-88 opioid receptor, mu 1 Mus musculus 32-37 28074831-5 2017 Here we investigate the role of RGS9-2 in regulating responses to oxycodone, an MOR agonist prescribed for the treatment of severe pain conditions that has addictive properties. Oxycodone 66-75 opioid receptor, mu 1 Mus musculus 80-83 34153316-2 2021 We herein report in vitro and in vivo characterization of two small molecules from a chemical series of MOR PAMs that exhibit: (i) MOR PAM activity and receptor subtype selectivity in vitro, (ii) a differential potentiation of the antinociceptive effect of oxycodone, morphine, and methadone in mouse models of pain that roughly correlates with in vitro activity, and (iii) a lack of potentiation of adverse effects associated with opioid administration, such as somatic withdrawal, respiratory depression, and analgesic tolerance. Oxycodone 257-266 opioid receptor, mu 1 Mus musculus 104-107 31778689-0 2020 Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. Oxycodone 35-44 opioid receptor, mu 1 Mus musculus 16-21 28653080-1 2017 INTRODUCTION: Non-medical use of prescription opioids such as the mu opioid receptor (MOP-r) agonist oxycodone is a growing problem in the USA and elsewhere. Oxycodone 101-110 opioid receptor, mu 1 Mus musculus 66-84 28653080-1 2017 INTRODUCTION: Non-medical use of prescription opioids such as the mu opioid receptor (MOP-r) agonist oxycodone is a growing problem in the USA and elsewhere. Oxycodone 101-110 opioid receptor, mu 1 Mus musculus 86-91 32424771-1 2021 Mu opioid receptors (MOR-1) mediate the biological actions of clinically used opioids such as morphine, oxycodone, and fentanyl. Oxycodone 104-113 opioid receptor, mu 1 Mus musculus 21-26 32859725-5 2020 We show that MOR deletion from D1 neurons reduced opioid (morphine and oxycodone)-induced hyperlocomotion whereas deleting MORs from A2a neurons resulted in enhanced opioid-induced locomotion, and deleting MORs from D2 or ChAT neurons had no effect. Oxycodone 71-80 opioid receptor, mu 1 Mus musculus 13-16 32259060-0 2019 Oxycodone-Mediated Activation of the Mu Opioid Receptor Reduces Whole Brain Functional Connectivity in Mice. Oxycodone 0-9 opioid receptor, mu 1 Mus musculus 37-55 32259060-4 2019 We used pharmacological magnetic resonance imaging in mice to characterize MOR-mediated oxycodone effects on whole-brain functional connectivity (FC). Oxycodone 88-97 opioid receptor, mu 1 Mus musculus 75-78 32259060-12 2019 In conclusion, we demonstrate that oxycodone reduces brain communication in a MOR-dependent manner, and establish a preliminary whole-brain FC signature of oxycodone. Oxycodone 35-44 opioid receptor, mu 1 Mus musculus 78-81 25446355-1 2015 Abuse and addiction to prescription opioids such as oxycodone (a short-acting Mu opioid receptor (MOP-r) agonist) in adolescence is a pressing public health issue. Oxycodone 52-61 opioid receptor, mu 1 Mus musculus 78-96 27496654-6 2016 Systemic subcutaneous (s.c.) administration of oxycodone (above 40mg/kg) could induce a small but significant antinociceptive effect in MOR-KO mice by the tail flick test. Oxycodone 47-56 opioid receptor, mu 1 Mus musculus 136-139 27496654-9 2016 When oxycodone was injected directly into the brain of MOR-KO mice by intracerebroventricular (i.c.v.) Oxycodone 5-14 opioid receptor, mu 1 Mus musculus 55-58 27496654-11 2016 Delta-opioid receptor antagonists (naltrindole at 10nmol or ICI 154,129 at 20mug) completely blocked the supraspinal antinociceptive effect of oxycodone in MOR-KO mice. Oxycodone 143-152 opioid receptor, mu 1 Mus musculus 156-159 27614221-1 2016 Adolescent and young adult abuse of short-acting MOP-r agonists such as oxycodone is a pressing public health issue. Oxycodone 72-81 opioid receptor, mu 1 Mus musculus 49-54 25446355-1 2015 Abuse and addiction to prescription opioids such as oxycodone (a short-acting Mu opioid receptor (MOP-r) agonist) in adolescence is a pressing public health issue. Oxycodone 52-61 opioid receptor, mu 1 Mus musculus 98-103